


Amendments to and Listing of the Claims:

Please cancel claims 124, 143, 146, 150 and 162-166 and amend claim 145 so that the claims read as follows:

1-119. (canceled)

120. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a calix[4]pyrrole macrocycle having structure I:



that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen, at least one pyrrole ring comprises a non-hydrogen β -substituent and the macrocycle is noncovalently-complexed to a halide anion;

wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;


i) hydrogen, halide, hydroxyl, alkyl, alkenyl or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen and at least one even-numbered R substituent is other than hydrogen.

121. (canceled)

122. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a calix[4]pyrrole macrocycle having structure I:



I

that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen, at least one pyrrole ring comprises a non-hydrogen-substituted nitrogen atom and the macrocycle is noncovalently-complexed to a halide anion;

wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;


i) hydrogen, halide, hydroxyl, alkyl, alkenyl, or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen and at least one of $R_A - R_D$ is other than hydrogen.

123-126. (canceled)

127. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a calix[4]pyrrole macrocycle having structure I:



that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen and the macrocycle is noncovalently-complexed to a halide anion;
wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;

i) hydrogen, halide, hydroxyl, alkyl, alkenyl, or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen.

128. (previously presented) The pharmaceutical composition of claim 127 wherein the halide anion is chloride.

129. (previously presented) The pharmaceutical composition of claim 127 wherein the halide anion is fluoride.

130. (previously presented) The pharmaceutical composition of claim 127, wherein the halide anion is selected from the group consisting of chloride and fluoride.


131-140. (canceled)

141. (previously presented) The pharmaceutical composition of claim 120, wherein the halide anion is selected from the group consisting of chloride and fluoride.

142. (previously presented) The pharmaceutical composition of claim 122, wherein the halide anion is selected from the group consisting of chloride and fluoride.

143. (canceled)

144. (previously presented) A composition comprising a calix[4]pyrrole macrocycle having structure I:



I


that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen, at least one pyrrole ring comprises a non-hydrogen β -substituent and the macrocycle is noncovalently-complexed to a halide anion; wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;

i) hydrogen, halide, hydroxyl, alkyl, alkenyl or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen and at least one even-numbered R substituent is other than hydrogen; and wherein the macrocycle is attached to a solid support.

145. (currently amended) A composition comprising a calix[4]pyrrole macrocycle having structure I:



I

that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen, at least one pyrrole ring comprises a non-hydrogen-substituted nitrogen atom and the macrocycle is noncovalently-complexed to a halide anion ~~molecular or anionic species~~, wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;


i) hydrogen, halide, hydroxyl, alkyl, alkenyl, or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen and at least one of $R_A - R_D$ is other than hydrogen; and wherein the macrocycle is attached to a solid support.

146. (canceled)

147. (previously presented) A composition comprising a calix[4]pyrrole macrocycle having structure I:



that has 4 pyrrole rings linked in α positions via sp^3 hybridized *meso*-carbon atoms, wherein neither non-pyrrole substituent of the *meso*-carbon atoms is hydrogen and the macrocycle is noncovalently-complexed to a halide anion;

wherein $R_1 - R_{16}$ are independently substituents as listed in paragraph i) below, and $R_A - R_D$ are independently substituents as listed in paragraph ii) below;

i) hydrogen, halide, hydroxyl, alkyl, alkenyl, or alkynyl;

ii) hydrogen or alkyl;

wherein odd-numbered R substituents are other than hydrogen; and wherein the macrocycle is attached to a solid support.

148. (previously presented) The composition of claim 144, wherein the halide anion is selected from the group consisting of chloride and fluoride.

149. (previously presented) The composition of claim 145, wherein the halide anion is selected from the group consisting of chloride and fluoride.

150. (canceled)

151. (previously presented) The composition of claim 147, wherein the halide anion is selected from the group consisting of chloride and fluoride.

152. (previously presented) The composition of claim 144, wherein the solid support is selected from the group consisting of silica gel, alumina, polyacrylamide, polystyrene, sepharose, sephadex, agarose, clay, zeolite, Merrifield resin, and glass.

153. (previously presented) The composition of claim 152, wherein the solid support is a silica gel.

154. (previously presented) The composition of claim 153, wherein the silica gel is functionalized.

155. (previously presented) The composition of claim 154, wherein the functionalized silica gel is selected from the group consisting of aminopropyl silica gel, carboxylalkylated silica gel, chloroethylated silica gel and chloroalkylated silica gel.

156. (previously presented) The composition of claim 144, wherein the solid support is in a form of a capillary electrophoresis tube, an electrophoresis gel, a chromatography column, and a thin layer chromatographic support.

157. (previously presented) The composition of claim 145, wherein the solid support is selected from the group consisting of silica gel, alumina, polyacrylamide, polystyrene, sepharose, sephadex, agarose, clay, zeolite, Merrifield resin, and glass.

158. (previously presented) The composition of claim 157, wherein the solid support is a silica gel.

159. (previously presented) The composition of claim 158, wherein the silica gel is functionalized.

160. (previously presented) The composition of claim 159, wherein the functionalized silica gel is selected from the group consisting of aminopropyl silica gel, carboxylalkylated silica gel, chloroethylated silica gel and chloroalkylated silica gel.

161. (previously presented) The composition of claim 145, wherein the solid support is in a form of a capillary electrophoresis tube, an electrophoresis gel, a chromatography column, and a thin layer chromatographic support.

162-166. (canceled)

167. (previously presented) The composition of claim 147, wherein the solid support is selected from the group consisting of silica gel, alumina, polyacrylamide, polystyrene, sepharose, sephadex, agarose, clay, zeolite, Merrifield resin, and glass.

168. (previously presented) The composition of claim 167, wherein the solid support is a silica gel.

169. (previously presented) The composition of claim 168, wherein the silica gel is functionalized.

170. (previously presented) The composition of claim 169, wherein the functionalized silica gel is selected from the group consisting of aminopropyl silica gel, carboxylalkylated silica gel, chloroethylated silica gel and chloroalkylated silica gel.

171. (previously presented) The composition of claim 147, wherein the solid support is in a form of a capillary electrophoresis tube, an electrophoresis gel, a chromatography column, and a thin layer chromatographic support.